Armistice Capital, LLC Macrogenics Inc Transaction History
Armistice Capital, LLC
- $5.71 Billion
- Q2 2025
A detailed history of Armistice Capital, LLC transactions in Macrogenics Inc stock. As of the latest transaction made, Armistice Capital, LLC holds 5,960,000 shares of MGNX stock, worth $9.06 Million. This represents 0.13% of its overall portfolio holdings.
Number of Shares
5,960,000
Previous 6,296,000
5.34%
Holding current value
$9.06 Million
Previous $8 Million
9.81%
% of portfolio
0.13%
Previous 0.12%
Shares
14 transactions
Others Institutions Holding MGNX
# of Institutions
118Shares Held
52.3MCall Options Held
55.3KPut Options Held
35.9K-
Bellevue Group Ag Kuesnacht, V89.92MShares$15.1 Million0.27% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$8.21 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.21MShares$6.4 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.25MShares$4.94 Million0.02% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.18MShares$4.83 Million0.2% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $93.4M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...